AdipoPharma
Pre-clinicalWe are developing PATAS, a unique first-in-class insulin sensitizer that targets the adipocyte and that will treat insulin resistance, type 2 diabetes and associated comorbidities.
Founded
2017
Focus
RNA & Gene Therapy
About
We are developing PATAS, a unique first-in-class insulin sensitizer that targets the adipocyte and that will treat insulin resistance, type 2 diabetes and associated comorbidities.
Company Info
TypePrivate
Founded2017
LocationLyon, France
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
4P-Pharma
Phase 2 · Lille
Patheon
Pre-clinical · Lyon
ABL Diagnostics
Pre-clinical · Strasbourg
Acticor Biotech
Pre-clinical · Paris
Adjuvatis
Pre-clinical · Lyon
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile